首页
产品
黄页
商标
征信
会员服务
注册
登录
全部
|
企业名
|
法人/股东/高管
|
品牌/产品
|
地址
|
经营范围
发明名称
ANORDNING FOER UTBYTE AV ETT GASMASKFILTER I FOERORENAD LUFT UTAN KONTAMINATIONSRISK.
摘要
申请公布号
FI884586(A)
申请公布日期
1989.04.07
申请号
FI19880004586
申请日期
1988.10.05
申请人
INDUSTRIE PIRELLI SOCIETA' PER AZIONI;MINISTERO DELLA DIFESA - DIREZIONE GENERALE A.M.A.T.
发明人
CAPPA, GIULIO;MOSCATELLI, ROMANO
分类号
A62B9/04;(IPC1-7):A62B/
主分类号
A62B9/04
代理机构
代理人
主权项
地址
您可能感兴趣的专利
PLATFORM TECHNOLOGIES FOR SPONTANEOUSLY OCCURRING DISEASES
LIGHTING SYSTEM
NOVEL AMIDE DERIVATIVES OF STEROIDAL[3,2-C]PYRAZOLE COMPOUNDS WITH GLUCOCOTRICOID ACTIVITY
SURFACE MODIFICATION OF REVERSE OSMOSIS MEMBRANES BY HYDROPHILIC DENDRITIC POLYMERS
VARYING PROPERTIES ALONG LENGTHS OF TEMPERATURE LIMITED HEATERS
LOW TEMPERATURE MONITORING SYSTEM FOR SUBSURFACE BARRIERS
PROCESS FOR THE PRODUCTION OF 9-CIS RETINOIC ACID
METHOD FOR PRODUCING ALCOHOL COMPOUND
METHOD FOR EVALUATING AN INFLAMMATORY CONDITION USING CALIBRATED GENE EXPRESSION PROFILES
FLEXIBLE, SCRATCH RESISTANT RADIATION CURABLE INKJET INKS
INFORMATION DISSEMINATION IN A WIRELESS COMMUNICATION SYSTEM
ALCOHOL ALKOXYLATES AS ADJUVANTS FOR AGROCHEMICAL FORMULATIONS
TRPV1 AGONISTS AND FORMULATIONS CONTAINING THEM
INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH MODULATION OF H3 RECEPTORS
SYSTEM AND METHODS FOR EVALUATING PERFORMANCE OF AFTERMARKET VEHICLE PART SALES
ISOLATED ANTIBODY WHICH BINDS TO THE N-TERMINAL DOMAIN (NTD) OF GAMMA-HRG, IN-VITRO METHODS FOR DETECTING AND PURIFYING GAMMA-HRG USING SUCH ANTIBODY AND USE OF SUCH ANTIBODY IN THE PREPARATION OF MEDICAMENTS
POLYPEPTIDES COMPRISING A CONSECUTIVE SEOUENCE OF THE GAMMA-HRG,N-TERMINAL DOMAIN, NUCLEIC ACIDS, VECTORS, HOST CELLS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PRODUCING AND USE OF SUCH POLYPEPTIDES
INTERRUPT CONTROLLER UTILISING PROGRAMMABLE PRIORITY VALUES
THIAZOLE CARBOXYLIC ACIDS DERIVATIVES AND THEIR USE IN THE TREATMENT OF PERIPHERAL NERVE SYSTEM DISORDERS
ANTIBODY DIRECTED AGAINST A POLYPEPTIDE THAT INTERACTS WITH PARKIN AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
